Fjarde Ap-fonden’s Pulmonx LUNG Stock Holding History

Fjarde Ap-fonden’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52K	Hold	40,000	–	–	﹤0.01%	512
2026 Q1	$51.6K	Hold	40,000	–	–	﹤0.01%	528
2025 Q4	$88.4K	Sell	40,000 -36,253	-48%	-$68.2K	﹤0.01%	495
2025 Q3	$124K	Hold	76,253	–	–	﹤0.01%	454
2025 Q2	$197K	Buy	+76,253	New	+$301K	﹤0.01%	487

Other funds holding LUNG

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Fjarde Ap-fonden's LUNG Position: Q2 2026 in Review

Fjarde Ap-fonden held its Pulmonx (LUNG) position steady in Q2 2026 at 40,000 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #512.

Fjarde Ap-fonden first reported a position in LUNG in Q2 2025 and has held it in 5 quarters since. The position peaked at $197K in Q2 2025. 108 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

Fjarde Ap-fonden held 40,000 shares of Pulmonx worth $52K as of Q2 2026.
Fjarde Ap-fonden left its Pulmonx share count unchanged in Q2 2026.
Pulmonx made up ﹤0.01% of Fjarde Ap-fonden's portfolio in Q2 2026, its #512 holding.
Fjarde Ap-fonden first reported a position in Pulmonx in Q2 2025 and has held it in 5 quarters since.
Fjarde Ap-fonden's Pulmonx position peaked at $197K in Q2 2025.
108 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.